[go: up one dir, main page]

NO20035025L - Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet. - Google Patents

Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.

Info

Publication number
NO20035025L
NO20035025L NO20035025A NO20035025A NO20035025L NO 20035025 L NO20035025 L NO 20035025L NO 20035025 A NO20035025 A NO 20035025A NO 20035025 A NO20035025 A NO 20035025A NO 20035025 L NO20035025 L NO 20035025L
Authority
NO
Norway
Prior art keywords
osteopontin
prevention
treatment
antagonist
activity
Prior art date
Application number
NO20035025A
Other languages
English (en)
Other versions
NO20035025D0 (no
Inventor
Ursula Boschert
Georg Feger
Raghuram Selvaraju
Ruben Papoian
Lilia Bernasconi
Original Assignee
Merck Serono As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono As filed Critical Merck Serono As
Publication of NO20035025L publication Critical patent/NO20035025L/no
Publication of NO20035025D0 publication Critical patent/NO20035025D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
NO20035025A 2001-05-17 2003-11-12 Anvendelse av osteopontin for behandling og/eller for å hindre nevrologiskesykdommer NO20035025D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111296 2001-05-17
PCT/EP2002/005081 WO2002092122A2 (en) 2001-05-17 2002-05-08 Use of osteopontin for the treatment and/or prevention of neurologic diseases

Publications (2)

Publication Number Publication Date
NO20035025L true NO20035025L (no) 2003-11-12
NO20035025D0 NO20035025D0 (no) 2003-11-12

Family

ID=8177366

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035025A NO20035025D0 (no) 2001-05-17 2003-11-12 Anvendelse av osteopontin for behandling og/eller for å hindre nevrologiskesykdommer

Country Status (26)

Country Link
US (4) US7217687B2 (no)
EP (1) EP1389130B1 (no)
JP (2) JP4417632B2 (no)
KR (1) KR100947424B1 (no)
CN (2) CN1939538A (no)
AT (1) ATE555803T1 (no)
AU (1) AU2002312886B2 (no)
BG (1) BG108337A (no)
BR (1) BR0209812A (no)
CA (1) CA2443964A1 (no)
CZ (1) CZ20033109A3 (no)
EA (1) EA006655B1 (no)
EE (1) EE200300559A (no)
ES (1) ES2387082T3 (no)
HR (1) HRP20030840A2 (no)
HU (1) HUP0400005A3 (no)
IL (2) IL158867A0 (no)
MX (1) MXPA03010327A (no)
NO (1) NO20035025D0 (no)
NZ (1) NZ528852A (no)
PL (1) PL211763B1 (no)
SK (1) SK14232003A3 (no)
UA (1) UA85368C2 (no)
WO (1) WO2002092122A2 (no)
YU (1) YU89503A (no)
ZA (1) ZA200307956B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046719A1 (en) 2003-11-12 2005-05-26 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
EP1389306A2 (de) 2001-05-09 2004-02-18 BioVisioN AG Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien
US7282490B2 (en) 2001-11-21 2007-10-16 The Board Of Trustees Of The Leland Stanford Junior University Osteopontin-related compositions and methods
AU2003278205B2 (en) * 2002-06-25 2008-01-24 Aventis Pharmaceuticals Inc. Osteopontin, oligodendrocytes and myelination
AU2003258127A1 (en) * 2002-08-06 2004-02-23 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
MXPA05010414A (es) * 2003-03-28 2005-12-14 Applied Research Systems Uso de clusterina para el tratamiento y/o prevencion de enfermedades neurologicas perifericas.
RU2379975C2 (ru) * 2003-09-18 2010-01-27 Арла Фудс Амба Добавка в состав для детского питания
US7790687B2 (en) * 2005-02-18 2010-09-07 Proximagen Ltd. Treatment for neurodegeneration
US20060264371A1 (en) * 2005-02-18 2006-11-23 Proximagen Ltd. Treatment
CA2624916A1 (en) 2005-10-13 2007-04-26 Anthrogenesis Corporation Production of oligodendrocytes from placenta-derived stem cells
EP1870107A1 (en) * 2006-06-23 2007-12-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inducer of promyelocytic leukemia protein (PML) for treating polyglutamine expansion neurodegenerative diseases
WO2008086449A2 (en) * 2007-01-09 2008-07-17 Oregon Health & Science University Synthetic osteopontin peptides and methods of use
US20100069254A1 (en) * 2008-09-16 2010-03-18 Laree Hiser Cell Culture Model for Demyelination/Remyelination
KR101449100B1 (ko) 2011-04-21 2014-10-13 가톨릭대학교 산학협력단 신경세포 데브리스 제거용 오스테오폰틴
GB2493540A (en) * 2011-08-10 2013-02-13 Follicum Ab Agents for stimulating hair growth in mammals
KR101728808B1 (ko) * 2012-09-28 2017-04-20 한국생명공학연구원 아세카이니드 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물
AU2015308899B2 (en) * 2014-08-27 2020-05-28 Dana-Farber Cancer Institute, Inc. Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
CN109600992A (zh) * 2016-05-20 2019-04-09 西达-赛奈医疗中心 治疗或预防阿尔茨海默病和相关病况的方法
WO2018098001A1 (en) * 2016-11-27 2018-05-31 Triton Algae Innovations, Inc. Method of purification of recombinant osteopontin from microalgae
PL3618845T3 (pl) 2017-05-04 2021-08-02 Follicum Ab Peptydy do leczenia cukrzycy
CN111315394A (zh) * 2017-08-15 2020-06-19 儿童医疗中心有限公司 作为用于神经元病变的治疗剂的骨桥蛋白
CN112752573A (zh) * 2018-05-25 2021-05-04 儿童医疗中心有限公司 治疗脊髓损伤的方法
TR201903865A2 (tr) * 2019-03-14 2020-09-21 Bogazici Ueniversitesi Amyotrofi̇k lateral skleroz tedavi̇si̇ i̇çi̇n i̇nterferon kullanimi
WO2021024265A1 (en) * 2019-08-08 2021-02-11 Ramot At Tel-Aviv University Ltd. Methods of treating non-infectious inflammatory disorders
CN111388654A (zh) * 2020-05-22 2020-07-10 南通大学 治疗脊髓损伤的药物、药物试剂盒及方法
WO2021246744A1 (ko) * 2020-06-02 2021-12-09 가톨릭대학교 산학협력단 오스테오폰틴 억제제를 유효성분으로 포함하는 퇴행성 신경계질환의 예방, 개선 또는 치료용 조성물
CN117720620B (zh) * 2023-12-13 2024-07-23 无锡市儿童医院 小分子多肽和其药物组合物、其制药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE300957T1 (de) 1998-12-22 2005-08-15 Genentech Inc Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
CA2370129A1 (en) 1999-04-15 2000-10-26 Children's Medical Center Corporation Methods and compositions for modulating an immune response
WO2000064460A2 (en) * 1999-04-23 2000-11-02 Sulzer Orthopedics Ltd. Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin
JP4027663B2 (ja) * 1999-10-04 2007-12-26 ネクター セラピューティックス エイエル，コーポレイション ポリマー安定化神経ペプチド

Also Published As

Publication number Publication date
US7297099B2 (en) 2007-11-20
PL211763B1 (pl) 2012-06-29
US7217687B2 (en) 2007-05-15
IL158867A0 (en) 2004-05-12
ZA200307956B (en) 2004-10-13
JP5036761B2 (ja) 2012-09-26
NZ528852A (en) 2005-12-23
ATE555803T1 (de) 2012-05-15
BG108337A (bg) 2004-12-30
HUP0400005A2 (hu) 2004-04-28
UA85368C2 (ru) 2009-01-26
SK14232003A3 (sk) 2004-05-04
MXPA03010327A (es) 2004-02-17
EP1389130B1 (en) 2012-05-02
HRP20030840A2 (en) 2005-08-31
EE200300559A (et) 2004-02-16
WO2002092122A2 (en) 2002-11-21
HK1067051A1 (en) 2005-04-01
US20080213234A1 (en) 2008-09-04
JP4417632B2 (ja) 2010-02-17
CA2443964A1 (en) 2002-11-21
PL367065A1 (en) 2005-02-21
EA006655B1 (ru) 2006-02-24
CN1286524C (zh) 2006-11-29
EP1389130A2 (en) 2004-02-18
YU89503A (sh) 2006-05-25
US20040235720A1 (en) 2004-11-25
WO2002092122A3 (en) 2003-03-06
ES2387082T3 (es) 2012-09-13
JP2009191082A (ja) 2009-08-27
HUP0400005A3 (en) 2012-09-28
CN1533283A (zh) 2004-09-29
CN1939538A (zh) 2007-04-04
KR100947424B1 (ko) 2010-03-12
AU2002312886B2 (en) 2007-10-25
JP2004536058A (ja) 2004-12-02
NO20035025D0 (no) 2003-11-12
EA200301253A1 (ru) 2004-06-24
KR20040008176A (ko) 2004-01-28
US20070225214A1 (en) 2007-09-27
US20050176639A1 (en) 2005-08-11
BR0209812A (pt) 2004-06-01
CZ20033109A3 (en) 2004-06-16
IL158867A (en) 2010-05-17

Similar Documents

Publication Publication Date Title
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
EE200300440A (et) Epotilooni analoogide ja kemoterapeutikumide kombinatsioon proliferatiivsete haiguste raviks
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
BR0308452A (pt) composições farmacêuticas e métodos de preparação de composição farmacêutica
WO2004006858A3 (en) Compounds, compositions, and methods employing same
EP1539234A4 (en) METHOD FOR PREVENTING OR TREATING CELL MALIGNITY BY ADMINISTERING CD2 ANTAGONISTS
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2003080582A3 (de) Fredericamycin-derivate
WO2006002437A3 (en) Treatment of conditions involving demyelination
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
EE05357B1 (et) Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
UA85187C2 (en) 2-aminobenzoyl derivatives
WO2005123113A3 (en) Interferon compositions and methods of use thereof
NO20072048L (no) Anvendelse av IL-17F for behandling og/eller forebygging av neurologiske sykdommer.
EA200400296A1 (ru) Применение ингибиторов il-18 при расстройствах в виде гиперчувствительности
WO2003064394A8 (de) 5-ring heterozyklen zur verwendung als antiviral mittel
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
WO2003027295A3 (en) Methods for diagnosis and treatment of diseases associated with altered expression of jak1
AU2003287513A8 (en) Inhibitors of beta-secretase, and their use for the prevention or treatment of alzheimer's disease or mild cognitive impairment

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application